Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are a woman who has been diagnosed with triple-negative breast cancer (a specific type of breast cancer), confirmed by a lab test or biopsy
- You are between 19 and 70 years old
- You are generally able to carry out daily activities with little or no limitation (confirm with trial site)
- Your breast cancer has been confirmed as Stage II or Stage III
- Your treatment plan includes a specific sequence of chemotherapy drugs called paclitaxel/carboplatin followed by AC chemotherapy, given before surgery
- Your blood, kidney, and liver are working well enough to safely take part, based on recent blood test results (confirm with trial site)
- You are willing and able to sign a consent form and follow the study requirements
Who may not be able to join:
- You have previously received chemotherapy treatment
- You have previously been treated with a type of medication used to boost white blood cell production (called G-CSF or pegylated G-CSF)
- You have a history of serious liver or kidney disease, or other conditions that may affect your bone marrow (confirm with trial site)
- You have had radiotherapy within the last 4 weeks before the study begins
- You currently have an active infection or inflammatory condition that is not under control
- You have received a blood transfusion within the last 60 days before the study begins
- You are pregnant, breastfeeding, or not willing to use a suitable method of contraception
- The trial doctor has any other medical reason to consider you unsuitable for participation (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gun Min Kim, Professor, Severance Hospital
Phone: 02-2228-8126
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Febrile Neutropenia (FN)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.